Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report

Medical and Pediatric Oncology

Volumn 40, Issue 1, 2003, Pages 66-69

  Sagar, T G ^a   Chandra, Anita ^a   Raman, S G ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DRUG EFFICACY; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; VOMITING;

EID: 0037210155     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10017     Document Type: Article

References (15)

1. Buyukpamukcu M, Atahan L, Caglar M, et al. Hodgkin disease in Turkish children: Clinical characteristics and treatment results of 210 patients. Pediatr Hematol Oncol 1999;16:119-129.
2. Shanta V, Sastri DVLN, Sagar TG, et al. A review of Hodgkin disease at the Cancer Institute, Madras. Clin Oncol 1982;8:5-15.
3. Lobo Sanahuja F, Garcia I, Barrantes JC, et al. Pediatric Hodgkins disease in Costa Rica: Twelve years experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol 1994;22:398-403.
4. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin disease. Cancer Res 1996;26:1063.
5. Carbone PP, Kalpan HS, Musshoff K, et al. Report of the committee on Hodgkin disease staging classification. Cancer Res 1971;31:1860-1861.
6. Montoto S, Camos M, Lopez-Guillermo, et al. Hybrid chemotherapy, consisting of cyclophosphamide, vincristine, procarbazine, prednisolone, doxorubcin, bleomycin and vinblastine (C - MOPP/ABV) as first line treatment for patients with advanced Hodgkin disease. Cancer 2000;88:2142-2148.
7. Kaplan GL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-463.
8. 2/E in the log rank test for survival data on tumor incidence data. Biometrics 1973;29:579-584.
9. Sripada PV, Tenali SG, Vasudevan M, et al. Hybrid (COPP/ABV) therapy in childhood. Hodgkin disease a study of 53 cases during 1989-1993 at Cancer Institute, Madras. Pediat Haematol Oncol 1995;12:333-341.
10. Shankar AG, Ashley S, Radford M, et al. Does histology influence outcome in childhood Hodgkin disease? Results from the United Kingdom Children's Cancer Study group. J Clin Oncol 1997;15:2622-2630.
11. Schellong G. Pediatric Hodgkin disease treatment in the late 1990s. Ann Oncol 1998;9:115-119.
12. Wolf J, Engert A, Diehl V. Issue in the treatment of Hodgkin disease. Curr Opin Oncol 1998;10:396-402.
13. Oberlin O, Leverger G, Pacquement MA, et al. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin disease. The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602.
14. Andrieu JM, Ifrah N, Payen C, et al. Increased risk of second acute non lymphocytic leukemia after extended field radiation therapy combined with MOPP chemotherapy for Hodgkin disease. J Clin Oncol 1990;8:1148-1154.
15. Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemia after chemotherapy without mechlorethamine in childhood Hodgkin disease German-Austrian Pediatric Hodgkin Disease Group. J Clin Oncol 1997;15:2247-2253.